Mycosis Fungoides with Oral Involvement

Abstract

Oral mucous membrane involvement occurs uncommonly in mycosis fungoides and reports of it are scarce. We present two patients with severe involvement of the oral mucous membranes.

Expression of special AT-rich sequence-binding protein 1 is an independent prognostic factor in cutaneous T-cell lymphoma

“…These risk factors include basic demographics, skin T stage, the presence of extra-cutaneous disease, lymphadenopathy and peripheral blood involvement (4,(30)(31)(32)(33)(34)(35)(38)(39)(40)(41)(42). Other factors have also been proposed as potentially prognostic, and include: large-cell transformation, levels of serum lactate dehydrogenase, β2-microglobulin, eosinophilia and serum IL-2 receptor (43)(44)(45)(46).…”

Osteonecrosis of the Jaw in Association With Chemotherapy in the Setting of Cutaneous T-Cell Lymphoma

“…11 In reviewing the literature, a PubMed and Medline search was conducted using the following key words and combined searches: S ezary, T-cell, lymphoma, CTCL, mycosis fungoides, osteonecrosis, and oral. After a review of all the scientific literature in the English language, 23 reported cases of intraoral manifestations of CTCL were found, 6,11,[17][18][19][20][21][22][23][24][25][26][27][28][29] …”

Mycosis fungoides involving the oral cavity

“…Reports of oral cavity involvement are rare, although autopsy series suggest an incidence of up to 13% 1–3 . To the authors’ knowledge, only 34 cases have been reported in the English published literature since the first report in 1914 4–22 . Sirois et al reported the largest series of eight cases representing <1% incidence of oral manifestation in 824 patients with MF over a 25‐year period 4 .…”

“…Oral‐cavity involvement is rare, with only 34 reported cases in the published literature. Involvement of the oral cavity is usually associated with a poor prognosis as a result of systemic disease progression 1–19 . The aim of this case study is to document our experience with a patient diagnosed with oral‐cavity involvement with extracutaneous MF.…”